A recent genome-wide association study (GWAS) identified a genome-wide significant locus (rs11465988) in IRAK3 for esketamine efficacy of anti-depression (i.e., percentage change in symptom severity score compared with baseline). Here, IRAK3 is linked to depressive symptom measurement.